Exelixis Inc Area of Real Estate Property
Exelixis Inc (EXEL) had Area of Real Estate Property of 215.00 million sqft as of 2025-01-03, per its 10-K filed 2026-02-10.
Financial Statements › Notes
us-gaap:AreaOfRealEstateProperty · last filed 2026-02-10
- 2025-01-03: Area of Real Estate Property 215.00M sqft; Area of Real Estate Property as first filed 215.00K sqft.
| Period end | Area of Real Estate Property | Area of Real Estate Property as first filed |
|---|---|---|
| 2025-01-03 | 215.00M sqft 10-K · filed 2026-02-10 | 215.00K sqft 10-K · filed 2025-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |